2026-03-05FDA approves teclistamab in combination with daratumumab hyaluronidase-fihj for relapsed or refractory multiple myelomaTrial MajesTEC-3Drugs Tecvayli (teclistamab) · Anti-BCMA-CD3 bispecific antibody, daratumumab hyaluronidase-fihj · Anti-CD38 antibodyConditionPlasma cell
2025-07-02FDA grants accelerated approval to linvoseltamab-gcpt for relapsed or refractory multiple myelomaTrial LINKER-MM1Drug Lynozyfic (linvoseltamab-gcpt) · Anti-BCMA-CD3 bispecific antibodyConditionPlasma cell
2023-08-14FDA grants accelerated approval to elranatamab-bcmm for multiple myelomaDrug Elrexfio (elranatamab-bcmm) · Anti-BCMA-CD3 bispecific antibodyConditionPlasma cell
2022-10-25FDA approves teclistamab-cqyv for relapsed or refractory multiple myelomaTrials MajesTEC-1, MajesTEC-1Drug Tecvayli (teclistamab-cqyv) · Anti-BCMA-CD3 bispecific antibodyConditionPlasma cell